ADA-话题@MedSci

#ADA#

386篇内容 | 2652人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1264763, encodeId=1bac1264e63a1, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比, objectType=article, longId=205368, objectId=7c3220536802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c3220536802, replyNumber=0, likeNumber=52, createdTime=2021-01-07, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c3220536802, moduleTitle=KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c3220536802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264762, encodeId=547e1264e6261, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, objectType=article, longId=203864, objectId=69b5203864d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b5203864d9, replyNumber=0, likeNumber=69, createdTime=2020-12-01, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b5203864d9, moduleTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69b5203864d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264761, encodeId=95821264e61bc, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展, objectType=article, longId=202536, objectId=c48320253636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c48320253636, replyNumber=0, likeNumber=75, createdTime=2020-10-28, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c48320253636, moduleTitle=KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c48320253636)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264760, encodeId=9d471264e6078, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=NEJM：Upadacitinib治疗生物药难治性类风湿关节炎, objectType=article, longId=202158, objectId=6b4b202158b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b4b202158b8, replyNumber=0, likeNumber=92, createdTime=2020-10-17, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b4b202158b8, moduleTitle=NEJM：Upadacitinib治疗生物药难治性类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b4b202158b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264759, encodeId=d8701264e593a, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效, objectType=article, longId=202153, objectId=31d82021531a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31d82021531a, replyNumber=0, likeNumber=66, createdTime=2020-10-17, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31d82021531a, moduleTitle=J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31d82021531a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264758, encodeId=2f7e1264e58e5, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华, objectType=article, longId=201991, objectId=5d832019917b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d832019917b, replyNumber=0, likeNumber=67, createdTime=2020-10-13, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d832019917b, moduleTitle=靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d832019917b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264757, encodeId=b7b71264e578f, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=PUDF2020丨张俊清教授：从ADA新指南看Ⅱ型糖尿病综合优化管理, objectType=article, longId=201271, objectId=7b0d2012e108, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b0d2012e108, replyNumber=0, likeNumber=81, createdTime=2020-09-28, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b0d2012e108, moduleTitle=PUDF2020丨张俊清教授：从ADA新指南看Ⅱ型糖尿病综合优化管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b0d2012e108)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264756, encodeId=175f1264e5672, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, objectType=article, longId=201090, objectId=24af2010905f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af2010905f, replyNumber=0, likeNumber=60, createdTime=2020-09-24, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af2010905f, moduleTitle=ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af2010905f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264755, encodeId=72c41264e559b, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Cell Death & Disease：N-α-乙酰转移酶10蛋白对ADAM9的稳定作用能够促进雄激素非依赖性前列腺癌的进展 , objectType=article, longId=199555, objectId=756419955575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756419955575, replyNumber=0, likeNumber=85, createdTime=2020-08-18, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756419955575, moduleTitle=Cell Death & Disease：N-α-乙酰转移酶10蛋白对ADAM9的稳定作用能够促进雄激素非依赖性前列腺癌的进展 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756419955575)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264754, encodeId=eba81264e543d, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌, objectType=article, longId=199405, objectId=b6411994055d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6411994055d, replyNumber=0, likeNumber=61, createdTime=2020-08-15, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6411994055d, moduleTitle=Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6411994055d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264753, encodeId=f8211264e5316, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=FDA批准Humira生物类似物Hulio（adalimumab-fkjp）, objectType=article, longId=197353, objectId=402219e353f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=402219e353f8, replyNumber=0, likeNumber=105, createdTime=2020-07-12, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=402219e353f8, moduleTitle=FDA批准Humira生物类似物Hulio（adalimumab-fkjp）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=402219e353f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264752, encodeId=1c291264e527c, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=日本厚生劳动省批准Vadadustat治疗慢性肾病引起的贫血, objectType=article, longId=196852, objectId=aa351968524c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa351968524c, replyNumber=0, likeNumber=92, createdTime=2020-07-02, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa351968524c, moduleTitle=日本厚生劳动省批准Vadadustat治疗慢性肾病引起的贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa351968524c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264751, encodeId=46731264e51d5, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功, objectType=article, longId=196772, objectId=914c196e721f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914c196e721f, replyNumber=0, likeNumber=77, createdTime=2020-07-01, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914c196e721f, moduleTitle=Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=914c196e721f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264750, encodeId=38ca1264e50d8, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著, objectType=article, longId=196771, objectId=6ae3196e71e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ae3196e71e3, replyNumber=0, likeNumber=62, createdTime=2020-07-01, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ae3196e71e3, moduleTitle=Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ae3196e71e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264749, encodeId=b48a1264e4933, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=J Oral Facial Pain Headache：三种三叉神经损伤替代模型中的体感功能，疼痛和不适感的评估, objectType=article, longId=196537, objectId=571419653eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=571419653eaf, replyNumber=0, likeNumber=82, createdTime=2020-06-27, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=571419653eaf, moduleTitle=J Oral Facial Pain Headache：三种三叉神经损伤替代模型中的体感功能，疼痛和不适感的评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=571419653eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264748, encodeId=35ee1264e4888, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=J Oral Facial Pain Headache：富血小板血浆注射液对颞下颌关节骨关节炎患者疼痛减轻的效果, objectType=article, longId=196534, objectId=8ffa1965345a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ffa1965345a, replyNumber=0, likeNumber=61, createdTime=2020-06-27, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ffa1965345a, moduleTitle=J Oral Facial Pain Headache：富血小板血浆注射液对颞下颌关节骨关节炎患者疼痛减轻的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ffa1965345a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264747, encodeId=43e51264e4795, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, objectType=article, longId=195939, objectId=e40a195939e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40a195939e1, replyNumber=0, likeNumber=80, createdTime=2020-06-17, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40a195939e1, moduleTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40a195939e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264746, encodeId=30511264e4624, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=28, createdTime=2020-06-10, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264745, encodeId=a75b1264e45bb, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Blood：ADAMTS13的开放构象——亚临床iTTP的新生物标志物, objectType=article, longId=194081, objectId=8276194081a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8276194081a5, replyNumber=0, likeNumber=58, createdTime=2020-05-14, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8276194081a5, moduleTitle=Blood：ADAMTS13的开放构象——亚临床iTTP的新生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8276194081a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1264744, encodeId=a9cf1264e44a5, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, objectTitle=Lancet：Secukinumab vs adalimumab用于治疗银屑病关节炎, objectType=article, longId=193804, objectId=db0219380405, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db0219380405, replyNumber=0, likeNumber=122, createdTime=2020-05-10, rootId=0, userName=般若傻瓜, userId=ad9f79, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db0219380405, moduleTitle=Lancet：Secukinumab vs adalimumab用于治疗银屑病关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db0219380405)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ADA

2020-05-29

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

KRAS抑制剂Adagrasib与Sotorasib治疗肺癌对比

2021-01-07

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

NICE拒绝了诺华的Adakveo（crizanlizumab）

2020-12-01

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

KRAS抑制剂adagrasib治疗非小细胞肺癌，83%应答患者无疾病进展

2020-10-28

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

NEJM：Upadacitinib治疗生物药难治性类风湿关节炎

2020-10-17

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

J Clin Oncol：新型LSD1抑制剂Iadademstat单一治疗复发/难治性AML初露成效

2020-10-17

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

靶向ADAMTS5骨关节炎新型纳米抗体，默克以5000万欧元授予给诺华

2020-10-13

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

PUDF2020丨张俊清教授：从ADA新指南看Ⅱ型糖尿病综合优化管理

2020-09-28

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADAURA III期临床研究结果公布：奥希替尼治疗中枢神经系统转移可改善无病生存期

2020-09-24

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Cell Death & Disease：N-α-乙酰转移酶10蛋白对ADAM9的稳定作用能够促进雄激素非依赖性前列腺癌的进展

2020-08-18

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Clin Cancer Res：WEE1激酶抑制剂adavosertib联合化疗治疗TP53突变型卵巢癌

2020-08-15

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

FDA批准Humira生物类似物Hulio（adalimumab-fkjp）

2020-07-12

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

日本厚生劳动省批准Vadadustat治疗慢性肾病引起的贫血

2020-07-02

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功

2020-07-01

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Gastroenterology：Upadacitinib治疗中重度活动性溃疡性结肠炎II期临床效果显著

2020-07-01

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

J Oral Facial Pain Headache：三种三叉神经损伤替代模型中的体感功能，疼痛和不适感的评估

2020-06-27

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

J Oral Facial Pain Headache：富血小板血浆注射液对颞下颌关节骨关节炎患者疼痛减轻的效果

2020-06-27

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险

2020-06-17

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2020-06-10

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Blood：ADAMTS13的开放构象——亚临床iTTP的新生物标志物

2020-05-14

般若傻瓜 (审核中...)

前往app查看评论内容

#ADA#

Lancet：Secukinumab vs adalimumab用于治疗银屑病关节炎

2020-05-10

科室
- - 订阅+
  - 更多科室
工具
服务